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Many pathogens enter the body via mucosal
surfaces. To prevent infection via this route, a
protective secretory IgA response is required.
Traditional parenteral vaccines primarily
induce IgM and IgG responses, whereas
mucosal vaccination, for example via the nasal
or oral route, is able to elicit both an IgG and
a secretory IgA response. Recently, expression
of vaccine antigens in plants has been explored
as an approach to facilitate oral vaccination
(Kong et al. 2001; Ma et al. 2003; Tacket
et al. 2000; Webster et al. 2002). 
Plant-based oral vaccines have several
advantages over traditional parenteral vac-
cines. Their production is more economical
and their delivery is safer, as needles and ani-
mal products are not used (Lauterslager et al.
2001; Streatﬁeld et al. 2001). Plant cells also
provide protection to the antigen during
long-term storage, transport at ambient tem-
perature, and as it passes through the harsh
environment of the stomach (Chikwamba
et al. 2003). Most important, plants do not
carry pathogens that are harmful to humans
and animals (Streatﬁeld et al. 2001).
Our work focuses on transgenic maize
expressing the B subunit of the Escherichia coli
heat-labile toxin (LT-B). Previous studies have
shown that this maize is both immunogenic,
eliciting the production of secretory IgA upon
oral administration to mice, and protective
against challenge with the holotoxin (LT)
(Chikwamba et al. 2002). LT-B is expressed
within the starch granules of the maize seed as
demonstrated by Chikwamba et al. (2003).
Because of this natural encapsulation, maize-
expressed LT-B is protected against harsh
environmental conditions including high tem-
peratures and enzyme degradation, while puri-
fied recombinant LT-B is not (Chikwamba
et al. 2003). In addition, the natural encapsu-
lation in maize starch granules may provide
better protection and stability than other
plant-produced vaccines such as potato,
tomato, or tobacco. This increased stability
should lead to improved immunogenicity. 
The enhanced stability of maize-expressed
LT-B is highly desirable for oral vaccine pro-
duction, storage, and effectiveness; however,
LT-B and its stability are also a concern in
regard to environmental contamination and/or
accidental consumption by humans and
domestic animals. Safety issues remain that
must be addressed. The use of transgenic maize
to produce a vaccine component opens the pos-
sibility for low-dose antigen exposure of work-
ers involved in its production or of consumers
should the product inadvertently occur in foods
(Wolt et al. 2006). Low-dose exposures have
implications for product efficacy, which we
address in this article. Furthermore, as
immunogenicity is highly sensitive, evidence of
immunogenic effects at low doses helps to set
the lower bound for subsequent considerations
of dose-dependent allergenic potential. Thus,
we must determine the minimum dose for
which no immune stimulation occurs upon
accidental consumption. 
The work we present here focuses on
determining the immunogenicity of maize
transgenic for LT-B in an intermittent feeding
schedule and identifying a maximum nonim-
munostimulatory dose. We hypothesized that
some low levels of LT-B could stimulate non-
detectable levels of speciﬁc antibody but result
in immune priming—an ability to induce the
production of memory B cells that can later
respond to the same antigen and produce spe-
ciﬁc IgG or IgA. We deﬁned immune priming
as a 4-fold increase of antibody (IgG or IgA)
over background after a 20-µg LT-B booster
exposure (Tacket 2005; Tacket et al. 1998,
2004). Because of the high degree of speci-
ﬁcity and sensitivity of the immune response
to the highly immunogenic LT-B, doses of
maize-derived LT-B that do not prime or
stimulate the immune response should be
considered an environmentally safe threshold.
Materials and Methods
Preparation of maize pellets. Production of
maize transgenic for LT-B (seeds from 4th-
generation transgenic plants) and preparation
of the maize seed pellets were carried out as
described previously (Chikwamba et al. 2002).
The pellets were formed by combining appro-
priate amounts of ground transgenic maize
seed with ground nontransgenic (nt) maize
seed to ensure that each pellet was a consistent
size and contained the amount of LT-B indi-
cated for each group. For the second study, we
prepared the lowest doses (0.0002–0.02 µg
LT-B) by mixing the ground transgenic maize
seed with ground nt maize seed 1:300 to make
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BACKGROUND: Transgenic maize, which produces the nontoxic B subunit of the Escherichia coli
heat-labile toxin (LT-B) in seed, has proven to be an effective oral immunogen in mice. Currently, there
is considerable concern over accidental consumption of transgenic maize expressing LT-B by humans
and domestic animals. We have yet to deﬁne nonimmunogenic levels of transgenic LT-B when ingested. 
OBJECTIVES: Our goal in this study was to determine the highest dose of LT-B orally administered
in mice that does not result in a measurable immune response. We deﬁned an immune response as
specific serum or mucosal IgG or IgA significantly greater than background after three feedings
(0.0002–20 µg) or a priming response induced by the intermittent feeding. 
METHODS: We fed transgenic maize pellets on days 0, 7, 21, and 49 and collected serum and fecal
samples weekly. Serum was analyzed for LT-B–speciﬁc IgG and IgA, and feces was analyzed for
LT-B–speciﬁc IgA.
RESULTS: We observed a dose-dependent anti-LT-B antibody response with high speciﬁc antibody
concentrations in groups fed high doses (0.2, 2, 20 µg) of LT-B maize. Mice fed 0.02 µg LT-B
demonstrated immune priming in 62.5% of the animals. Mice that were fed ≤ 0.002 µg LT-B
showed no increase in speciﬁc antibody nor did they demonstrate immune priming, indicating that
0.002 µg LT-B was the highest nonimmunogenic dose tested. 
CONCLUSION: Our results demonstrate that LT-B derived from transgenic maize is immunogenic at
nanogram levels when orally administered to mice.
KEY WORDS: adulterated food, genetically modiﬁed organism, heat-labile toxin, inadvertent exposure,
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weight of maize seed in each pellet was 0.811 g
for the ﬁrst study and 0.937 g for the second
study. The ground maize seed for each pellet
was mixed with 600–700 µL of phosphate-
buffered saline (PBS) [1.9 mM NaH2PO4,
8.1 mM Na2HPO4, 0.15 M NaCl (pH 7.3)],
formed into a pellet, and air-dried overnight.
Ground nt maize seed was used to make pel-
lets of similar weight to feed to the negative
control groups. 
To ensure that LT-B content in the
maize remained constant during pellet for-
mation, one extra pellet was formed per dose
per feeding for analysis of LT-B content
using a ganglioside-dependent ELISA. Three
to four pellets of each type were frozen until
ELISA analysis of LT-B content (four sam-
ples from each pellet). We detected no
significant differences between the intended
amount and the amount measured with
ELISA for all pellets except the 20-µg pellets.
The 20-µg pellets had higher amounts of
LT-B than intended. These amounts ranged
from 26.5–40.8 µg LT-B per pellet instead of
20 µg (p < 0.0001; data not shown). Despite
the range of measured LT-B in the 20-µg
pellets, we will continue to refer to this dose
as the nominal 20-µg dose and animals given
that dose as the 20-µg group.
Oral immunization of mice. We obtained
4- to 6-week-old female BALB/c mice from
Harlan Sprague Dawley (Indianapolis, IN,
USA) and allowed them a 2-week acclimation
period with a 12-hr reversed light/dark cycle
before beginning the experiment with lights
on at 2100 hr. The mice were housed four per
cage in the Iowa State University (ISU) animal
facility with food and water ad libitum.
Animals were treated humanely, and all pro-
cedures were approved by the ISU Institutional
Animal Care and Use Committee. 
Before the maize seed pellets were fed to
the mice, the mice were fasted overnight (dur-
ing the light phase) with water ad libitum.
While eating the pellets, mice were housed
individually with water ad libitum and were
allowed to eat the pellet for 4 hr or until the
pellet was finished, typically a maximum of
6–8 hr for the slowest mice. Upon completion
of the pellet, the mice were returned to group
cages with mouse chow and water ad libitum. 
In the ﬁrst study, we divided mice into six
groups of four mice each. The experimental
groups were fed 0.02, 0.2, 2, or 20 µg LT-B
per pellet per feeding. The two control groups
were fed nt maize pellets. The maize pellets
were fed on days 0, 7, and 21. To test for
immune priming, on day 49 all mice were fed
a 20-µg LT-B pellet, including one group pre-
viously fed nt maize (nt + 20). In addition, one
nt group was fed nt maize pellets on day 49.
In the second study, we used the same
experimental design except that some mice
were fed lower doses of LT-B. The groups
consisted of mice fed 0.0002, 0.002, 0.02,
and 20 µg LT-B per pellet per feeding and
two groups fed nt maize. To test for immune
priming, on day 49 the mice were all fed
20 µg LT-B, except one nt group. Thus,
internal repeats of the nt, nt + 20, 0.02-, and
the 20-µg groups were included for a total of
eight mice receiving each of these treatments
over two experiments.
Sample collection and preparation. We
collected serum and fecal pellets before the ini-
tial dosing and weekly throughout both studies
to detect LT-B–specific serum IgG and IgA
concentrations and fecal IgA concentrations.
Blood was collected via the saphenous vein,
using heparinized capillary tubes and cen-
trifuged with serum separator gel (Vacutainer
Plus plastic serum tube; Becton Dickinson,
Franklin Lakes, NJ, USA) at 6,000 × g in a
bench top microcentrifuge (Jouan M14.11;
Thermo Electron Corp., Waltham, MA, USA)
for 10 min. The serum was collected in micro-
centrifuge tubes and stored at –20°C until ana-
lyzed for LT-B–speciﬁc IgG and IgA by ELISA
as described below.
Fecal pellets were collected from each
mouse, frozen, lyophilized, and stored at
–20°C. We extracted lyophilized pellets by
adding extraction buffer [0.05% NaN3,
10 µg/mL leupeptin (Sigma, St. Louis, MO,
USA), 0.25 mM PefablocSC ( Sigma) in PBS]
at 10 µL/mg of lyophilized feces, vortexing,
and extracting overnight at 4°C. Before analy-
sis, the samples were placed on a shaker
(Tekmar VXR-S10; Janke & Kunkel, Staufen,
Germany) at 1,000 rpm for 90 min, then cen-
trifuged at 6,000 × g for 10 min with serum
separator gel. The liquid extract was collected
and analyzed by ELISA for LT-B–speciﬁc IgA
as described below. 
Euthanization. Mice were euthanized on
day 57 for the ﬁrst study; for the second, half
the mice were euthanized on day 55 and the
other half on day 56. For both studies, mice
were euthanized with CO2. 
Lung lavage. After mice were euthanized
we performed lung lavages by exposing the
trachea, inserting a TomCat catheter (Kendall
Sovereign, Tyco Healthcare, Mansﬁeld, MA,
USA), and flushing the lungs twice with
0.8 mL sterile PBS. The samples were cen-
trifuged at 6,000 × g for 10 min to remove
cells and stored at –20°C until analysis for
LT-B–specific IgA by ELISA as described
below. 
ELISAs. We performed ELISAs for LT-B–
and LT-B–specific antibodies as previously
described (Chikwamba et al. 2002; Karaman
et al. 2006) unless otherwise noted. All mouse
samples, which were analyzed individually,
and reagents were added 50 µL/well, and
between each step wells were washed 4 times
with 100 µL/well PBST [0.05% Tween 20
(polyoxyethylene sorbitan monolaurate;
Sigma) in PBS]. 
Detection of LT-B–speciﬁc IgG and IgA.
Measurements of LT-B–specific IgG (serum
samples) and IgA (serum, fecal, and lung
lavage samples) were carried out as described
previously (Karaman et al. 2006) with minor
changes. Briefly, all fecal extracts were mea-
sured within 24 hr of extraction. Sample con-
centrations were determined by comparing to
a standard curve consisting of wells coated
with either puriﬁed mouse IgG (MOPC 21,
Sigma) with a range of 1.37–1000 ng/mL or
IgA (Bethyl Laboratories, Montgomery, TX,
USA) with a range of 0.46–400 ng/mL.
Samples were diluted appropriately to fall
within the linear range of the curve. End
point readings were taken at 405 nm using
the EL 340 microplate reader (Bio-Tek
Instruments, Inc., Winooski, VT, USA) and
data collected using KC Junior software (ver-
sion 1.17, Bio-Tek Instruments, Inc.) using a
four-parameter fit standard curve. Samples
reading below the standard curve were
reported as one-half the value of the lowest
detectable standard to permit log transforma-
tion of the data for statistical analysis.
Detection of LT-B in maize. We
extracted LT-B from ground maize or crushed
maize pellets equivalent to those used for feed-
ing using a sodium phosphate extraction
buffer [sodium phosphate buffer (pH 6.6)
25 mM; sodium chloride 100 mM; EDTA,
1 mM; Triton X-100, 0.1%] with protease
inhibitors (leupeptin, 10 µg/mL; PefablocSC,
0.25 mM) at 10 µL/mg maize. Samples were
extracted with buffer shaking at 1,000 rpm at
37°C for 2 hr. The extract was collected by
centrifuging at 6,000 × g for 15 min in a
bench top microcentrifuge.
We determined LT-B content of maize
extract using a ganglioside-dependent ELISA
as described previously (Chikwamba et al.
2002) with minor changes. LT-B was detected
by incubating with rabbit anti-LT-B antibody
(diluted 1:10,000; Immunology Consultants
Laboratory, Inc., Newberg, OR, USA), then
incubating with biotin-conjugated goat anti-
rabbit IgG (diluted 1:5000; Sigma). The sec-
ondary antibodies were detected using
streptavidin-horse radish peroxidase (diluted
1:1000; Becton Dickinson), then incubating
with ABTS (3-ethylbenzthiazoline-6-sulfonic
acid; Sigma) substrate buffer [0.1 M citric
acid, 0.55 mM ABTS (pH 4.25)]. Values
were determined by comparing to a standard
curve of puriﬁed bacterial LT-B (provided by
J. Clements).
Statistical analysis. We analyzed the data
with general analysis of variance, using LT-B
dose and sample day as variables in the model.
Because of unequal variance between the
groups, the antibody data were log trans-
formed before analysis (Kirk 1982). Each
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0.05) from the prefeed date was further ana-
lyzed by between group contrasts for that day.
Analysis was conducted using the statistical
software Statistix (version 8; Analytical
Software, Tallahassee, FL, USA). We used
non-log-transformed data for graphs. Immune
responses were divided into two types and
defined as follows: An antibody response is
demonstrated by antibody concentrations sig-
niﬁcantly higher (p < 0.05) than those of the
nt-fed group, and immune priming is demon-
strated by antibody concentrations 4-fold
higher than those of the nt-fed group 5–6 days
after a 20-µg LT-B dose (Tacket 2005; Tacket
et al. 1998, 2004).
Results
LT-B–induced dose-dependent response with
immune priming. In our ﬁrst experiment we
tested the immunogenicity of various doses of
LT-B from transgenic maize. To identify a
nonimmunostimulatory dose, we tested
10-fold differences of LT-B doses (ranging
from 0.02 to 20 µg per feeding) using an
intermittent feeding regimen previously
shown to induce a robust antibody response
in 28 days with pellets fed on days 0, 7, and
21 (Chikwamba et al. 2002).
Serum IgG. Intermittent feeding of
LT-B induced a dose-dependent serum
IgG response (Figure 1A). Mice fed 20 µg
LT-B had low serum IgG levels (0.318 ±
0.061 µg/mL) but these levels were signifi-
cantly higher than those of mice fed nt maize
(0.169 ± 0.018 µg/mL) by day 6 (p = 0.0035)
and were significantly higher than all other
groups on days 13–48 (p < 0.05). Mice fed 2
and 0.2 µg LT-B had signiﬁcantly higher con-
centrations of IgG by day 13 compared with
the nt group (p < 0.0001 for both groups on
days 13–48). The concentrations of specific
IgG in the 0.02-µg group were low, but
demonstrated a signiﬁcant increase on day 27
(0.298 ± 0.039 µg/mL) compared with the nt
group (0.159 ± 0.018 µg/mL) (p = 0.0038),
with signiﬁcance continuing through day 48
(p ≤ 0.0089). 
The peak antibody concentration for all
groups was reached on day 55, 6 days after the
20-µg booster as seen in Figure 1B. After the
booster, LT-B–speciﬁc IgG levels were signiﬁ-
cantly increased for mice in the 20-, 2-, 0.2-,
and 0.02-µg groups compared with the nt
group (p ≤ 0.0065). All mice in the 20-, 2-, and
0.2-µg groups demonstrated antibody levels at
least 4 times higher than nt mice on day 55. In
the 0.02-µg group, two of four (50%) mice had
antibody levels 4 times those of the nt control
group, which is indicative of immune priming.
There was no statistical difference between
either of the nt groups for serum IgG through-
out the study, even after feeding one group
20 µg LT-B on day 49 (p = 0.7085). 
Serum IgA. As with serum IgG, feeding
LT-B generally induced a dose-dependent
response in serum IgA (Figure 2A). Signiﬁcantly
increased antibody levels compared with those
in the nt group were observed in the 20-, 2-,
Beyer et al.
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Figure 1. Study 1 serum IgG concentrations in response to three intermittent feedings of LT-B (A) or a booster dose of 20 µg LT-B given on day 49 (B). (A) LT-B
feeding days are indicated by the arrows. Antibody concentrations are presented as mean ± SE. (B) Group means are represented as bars (- - -). For both A and
B, n = 4 mice per group, except for the nt group, which had n = 8 on days –3 to 48. 
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Figure 2. Study 1 serum IgA concentrations in response to three intermittent feedings of LT-B (A) or a booster dose of 20 µg LT-B given on day 49 (B). (A) LT-B
feeding days are indicated by the arrows. Antibody concentrations are presented as mean ± SE. (B) Group means are represented as bars (- - -). For both A and
B, n = 4 mice per group, except for the nt group, which had n = 8 on days –3 to 48.
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Day 21and 0.2-µg LT-B groups beginning on day 13
and continuing to the end of the study (p ≤
0.0071) (Figure 2A,B). The 0.2-µg group
demonstrated higher but not signiﬁcantly dif-
ferent levels of antibody compared with the 2-
and 20-µg groups on days 13 and 20.
Additionally, the antibody serum IgA levels of
0.2-µg group remained higher than those of the
2-µg group until the end of study. Although we
are not sure why the lower dose resulted in
higher antibody levels, we are certain that it was
not a technical error, as the same serum samples
demonstrated a dose-dependent IgG response.
We hypothesized that perhaps a lower dose,
such as 0.2 µg LT-B, is optimal for stimulating
an early IgA response Also, the high average
value was not just due to one outlier in the
0.2-µg group, as on day 13, three of four mice
in the 0.2-µg group had higher antibody levels
than the mice in the 2-µg group for serum IgA.
Because of the short half-life of IgA,
obtaining a high level of IgA antibody signiﬁ-
cantly different from that in the nt group was
not always observed with consecutive sample
dates. This was demonstrated by the 0.02-µg
group, which was marginally different from the
nt group (p = 0.0785) on day 13 and signiﬁ-
cantly different on days 27, 34, 48, and 55 (p ≤
0.0351). On day 55, three of four (75%) mice
in the 0.02-µg LT-B group appeared to have
responded to the 20-µg booster dose with
LT-B–speciﬁc IgA levels 4 times higher than
those of the nt control group (Figure 2B), sug-
gesting that these three mice were immunolog-
ically primed. There was no significant
difference between the nt and nt +20 groups
throughout the study (p = 0.9481 on day 55)
and none of the mice (zero of four) in the nt +
20 group had antibody levels 4 times higher
than those of the nt group on day 55. Because
of a lack of samples, no data from day 6 of the
study were obtained. 
Fecal IgA. Mucosal IgA was measured in
extracts of lyophilized fecal material and
expressed as micrograms per gram of fecal
material as shown in Figure 3. Mice fed 20 µg
LT-B had signiﬁcantly higher levels of IgA in
fecal material than those of the nt group on
day 13 (p < 0.0001) and again on day 27
throughout the rest of the study (p ≤ 0.0019).
The 2-µg group had signiﬁcantly higher levels
than those of the nt group on days 13, 27, 34,
41, and 55 (p ≤ 0.0371). Similar to the serum
IgA results, mice fed 0.2 µg LT-B had levels of
fecal IgA that were significantly higher than
those of the nt group by day 13 (p < 0.0001)
and throughout the remaining sample dates
(p ≤ 0.0384).
Fecal IgA levels were statistically higher in
the 0.2 µg group than those in the 2 µg LT-B
group on days 13, 20, and 55 (p < 0.05).
Again, this was not because of an outlier in
the group, as on all those dates at least three
of four mice in the 0.2-µg group had higher
antibody levels than those of the mice in the
2-µg group.
Fecal antibody concentrations of mice fed
0.02 µg LT-B reached statistical significance
on days 20, 27, 34, and 55 (p ≤ 0.0163) with
Immunogenicity of low doses of LT-B
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Figure 3. Study 1 fecal IgA concentrations in response to three intermittent feedings of LT-B (A) or a booster dose of 20 µg LT-B given on day 49 (B). (A) LT-B feed-
ing days are indicated by the arrows. Antibody concentrations are presented as mean ± SE. (B) Group means are represented by bars (- - -). For both A and B, n =
4 mice per group, except for the nt group, which had n = 8 on days –3 to 48. 
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Figure 4. Study 2 serum IgG concentrations in response to three intermittent feedings of LT-B (A) or a booster dose of 20 µg LT-B given on day 49 (B). (A) LT-B
feeding days are indicated by the arrows. Antibody concentrations are presented as mean ± SE. (B) Group means are represented by bars (- - -). For both A and
B, n = 4 mice per group, except for the nt group, which had n = 8 on days –3 to 48. 
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the those of the nt group on days 41 and 48
(p = 0.0515 and 0.0712, respectively). On
day 55, 1 week after the 20-µg booster, one
mouse in the 0.02-µg group had 4 times the
antibody concentration of that in the nt group
(Figure 3B), suggesting that immune priming
had occurred in one of four mice. The nt and
nt + 20 groups were not statistically different
throughout the study (p = 0.7278 on day 55).
Confirmation of 0.02-µg threshold for
immune priming. During the second inter-
mittent feeding study, antibody responses to
low doses of LT-B administered orally in
transgenic maize were measured. Because our
ﬁrst study demonstrated a signiﬁcant increase
in antibody concentrations and immune
priming in some mice fed 0.02 µg of LT-B,
we chose to repeat this dose and test two
doses, each 10-fold lower in order to identify
a nonimmunogenic dose. We also included a
20-µg LT-B dose as a positive control. Thus,
two groups were repeated from the first
experiment and two groups were new. As in
the first experiment, we looked for produc-
tion of serum and fecal antibody as well as
immune priming. 
Serum IgG. As seen in Figure 4A, mice
fed 20 µg LT-B had signiﬁcantly elevated lev-
els of serum IgG (0.296 ± 0.035 µg/mL) by
day 6 (p = 0.0046) compared with the
nt group (0.201 ± 0.017 µg/mL) and had sig-
niﬁcantly higher levels throughout the study
(p < 0.0001 for all remaining sample dates),
reaching peak levels on day 54 that were
similar to those observed in the first study
(Figure 4B vs. Figure 1B). The 0.02-µg group
had marginally higher levels than those of the
nt group on days 27, 41, and 48 (p = 0.0535,
0.0594 and 0.0514, respectively) and signiﬁ-
cantly higher levels on days 34 and 54 (p =
0.0335 and 0.0257, respectively). No other
groups had IgG concentrations significantly
different from those of the nt group
(Figure 4A,B). On day 54 for the 0.02-µg
group, one of four (25%) animals demon-
strated an antibody level 4 times that of the nt
group (4.2 µg/mL vs. 0.2 µg/mL), suggesting
that immune priming had occurred in that
animal (Figure 4B). Despite that one animal
in the nt + 20 group demonstrated elevated
antibody concentrations after the 20-µg LT-B
booster, the increase may be the beginning of
primary response because the level of antibody
(1.4 µg/mL) is far below that of the primed
mouse in the 0.02-µg group (4.2 µg/mL).
Additionally, the nt + 20 group was not statis-
tically different from the nt group.
Serum IgA. The serum IgA concentrations
of the 20-µg LT-B group (0.5721 µg/mL)
were significantly higher than those of the 
nt group (0.0607 µg/mL) by day 6 (p =
0.0088 on day 6 and p < 0.0001 for all
remaining sample dates), as seen in Figure 5A.
The antibody concentrations of the 0.02-µg
group were marginally different from those of
the nt group on day 27 (p = 0.0548) and sig-
nificantly different on day 34 and all subse-
quent days (p ≤ 0.0294). No other group had
antibody concentrations signiﬁcantly different
from those of the nt group throughout the
study. Once again the 0.02-µg LT-B group
Beyer et al.
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Figure 5. Study 2 serum IgA concentrations in response to three intermittent feedings of LT-B (A) or a booster dose of 20 µg LT-B given on day 49 (B). (A) LT-B
feeding days are indicated by the arrows. Antibody concentrations are presented as mean ± SE. (B) Group means are represented by bars (- - -). For both A and
(B, n = 4 mice per group, except for the nt group, which had n = 8 on days –3 to 48. 
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Figure 6. Study #2 fecal IgA concentrations in response to three intermittent feedings of LT-B (A) or a booster dose of 20 µg of LT-B given on day 49 (B). (A) LT-B
feeding days are indicated by the arrows. Antibody concentrations are presented as mean ± SE. (B) Group means are represented by bars (- - -). For both A and
B, n = 4 mice per group, except for the nt group, which had n = 8 on days –3 to 48. 
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0.002 0.0002 0.02 0.002 0.0002had two of four (50%) mice that appeared to
be primed (Figure 5B). To calculate the level
of antibody 4 times higher than those of the
nt group for this data set, we used the data
from the nt + 20 group, as all mice in the nt
group had no detectable antibody on day 54.
No other group (0.0002 or 0.002 µg) had
responders by this standard.
Fecal IgA. The 20 µg LT-B group had anti-
body concentrations marginally higher than
those of the nt group by day 13 (p = 0.0574)
and signiﬁcantly higher by day 20 (p = 0.0046)
and throughout the remainder of the study (p ≤
0.0202), as seen in Figure 6A. The 0.02-µg
LT-B group did not have a signiﬁcant increase
in antibody concentrations compared with
those of the nt group; however, after the 20-µg
booster, one of four (25%) mice responded
with 4 times the antibody concentrations of
those of the nt group, suggesting immune
priming (Figure 6B). No animals fed lower
doses of LT-B responded by either measure.
IgA from lung lavages. Mucosal IgA was
measured in lung lavage fluid of euthanized
mice (Figure 7). The 20- and 0.02-µg LT-B
groups had signiﬁcantly elevated levels of IgA
compared with those of the nt group and the
negative control group, which was never fasted,
handled, or fed maize pellets (p < 0.0001 and
p = 0.0029, respectively). 
Frequency of immune priming with
0.02 µg LT-B. Although the fecal IgA mea-
surements in the second study for the 0.02-µg
group were not signiﬁcantly higher than those
of the nt group, this dose resulted in signiﬁ-
cant levels of antibody in all other measures
for both studies at least at one sample day
before the 20-µg booster as well as by day
54 or 55. Additionally, approximately half the
mice in both studies were primed, based upon
antibody levels at least 4-fold higher than
those of the nt group. One mouse in each
study demonstrated priming using all three
measures (serum IgG, serum IgA, and fecal
IgA), whereas all other mice responded in
only one or two of the measures (Table 1).
The rates of immune priming varied between
different measures (serum IgG vs. serum IgA
vs. fecal IgA), indicating that some are more
sensitive than others. We found serum IgA to
be the most sensitive, which is likely because
oral exposure to an antigen primarily elicits
an IgA response as opposed to IgG. Also, fecal
IgA is difﬁcult to measure accurately because
of the high rate of antibody breakdown in the
feces. Using our most sensitive measure,
serum IgA, we observed that the overall rate
of immune priming in mice fed 0.02 µg LT-B
intermittently is 62.5%.
Effect of maize consumption on mouse
weight. Upon euthanization, the weight of
each mouse was recorded. For both studies,
we found no significant difference between
mice fed transgenic maize compared with
mice fed nt maize (p ≥ 0.14). In addition, for
the second study, no significant difference
was detected between mice that were handled,
fasted, and fed transgenic or nt maize com-
pared with mice that were never handled,
fasted, or fed maize (p ≥ 0.11), thereby
demonstrating that the nt and transgenic
maize at the doses administered had no toxic
effects on the mice (data not shown).
Discussion
In this study we addressed the immunologic
effects in mice of accidental consumption of
low doses of maize transgenic for LT-B. The
doses fed to the mice included 20 µg LT-B, a
dose protective in vaccine studies, as well as
ﬁve additional doses, with each 10-fold lower
than the previous one (2, 0.2, 0.02, 0.002, and
0.0002 µg LT-B). The 20-µg dose was
included in both experiments as a positive con-
trol. Chikwamba et al. (2002) and Mason et al.
(1998) previously demonstrated that 10–50 µg
LT-B fed 3 times intermittently to mice results
in a protective level of antibody. Here we
demonstrate that the 20-µg functional dose
also results in a robust memory response that
elicited 2-fold increases in serum IgG and
10-fold increases in serum and fecal IgA.
Serum IgA represents a monomeric nonse-
creted form of IgA. Although the biological
function of serum IgA is unclear, differences in
the concentration of serum IgA between ani-
mals correlates with differences in mucosally
secreted IgA.
We have extended previous studies
(Chikwamba et al. 2003; Karaman et al.
2006) by testing doses of 0.0002, 0.002, 0.02,
0.2, 2, and 20 µg LT-B for serum IgG and
IgA as well as fecal IgA and we have observed a
dose-dependent antibody response. Only mice
that were fed ≥ 0.02 µg LT-B elicited signiﬁ-
cantly elevated levels of antibody. It should be
noted that although the antibody response in
the 0.02 µg group was low, it was signiﬁcantly
higher than that of the nt group in six of seven
measures. The biological relevance of the low
antibody concentration is underscored by the
fact that approximately half the mice in the
0.02-µg group demonstrated a 4-fold increase
in antibody when fed a 20-µg dose. No lower
dose resulted in an antibody response or
immune priming. From this study, we found
that serum IgA was the most sensitive measure
for detecting mice that had been immunologi-
cally primed. In addition, we identified
0.002 µg as the highest nonimmunostimula-
tory dose, one that resulted in neither an anti-
body response nor immune priming when fed
intermittently. 
Although we considered 0.02 µg LT-B a
dose that results in immune priming, not all
the mice in these groups resulted in a priming
response. Some animals had fair antibody
responses while others appeared to have no
response at all on days 54 or 55. One explana-
tion for this is that there is some variability
even between genetically inbred BALB/c mice
that becomes obvious when feeding a dose that
Immunogenicity of low doses of LT-B
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Figure 7. Study 2 lung lavage IgA concentrations on day 54 in response to a booster dose of 20 µg LT-B
given on day 49. Antibody concentrations are presented as mean ± SE with n = 4 mice per group. The
groups are labeled according to the amount of transgenic maize fed on days 0, 7, and 21 in micrograms.
The group nt + 20 is the nt group fed 20 µg on day 49. The nt group is the nt group fed all nt maize. The
negative control group was never handled, fasted, or fed maize.
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Table 1. Frequency [no of mice (%)] of immune prim-
ing in mice fed 0.02 µg LT-B 3 times intermittently. 
Experiment 
Sample 1 2 Total
Serum IgG 2/4a (50)b 1/4 (25) 3/8 (37.5)
Serum IgA 3/4 (75) 2/4 (50) 5/8 (62.5)
Fecal IgA 1/4 (25) 1/4 (25) 2/8 (25)
aNumber of primed mice/total number of mice tested.
bPercentage of primed mice of total mice tested.is borderline for inducing a response.
Alternatively, the amount of LT-B in the maize
fed to each mouse may not have been uniform.
Our group has observed that the finer the
transgenic maize kernels were ground, the
more LT-B could be extracted and detected in
ELISA (Chikwamba et al. 2002). Although the
extra pellets that we prepared and assayed were
all very close to containing 0.02 µg LT-B
(0.0226, 0.0184, and 0.0195 µg), perfect
homogenous mixes are not practical using
ground maize and it is not inconceivable that
one or more of the experimental pellets may
have been more variable in LT-B content. This
is more of a problem with borderline doses
than with the high, immunogenic doses used
as a functional vaccine.
Although there are many advantages to pro-
ducing LT-B in maize, there are also concerns
associated with genetically modiﬁed organisms
(Schmidt 2005). Because of the high immuno-
genicity of LT-B, even at low levels, intermit-
tent accidental consumption of maize
transgenic for LT-B could result in an antibody
response, immune priming, or both depending
on the dose ingested. Whether immune prim-
ing has a positive or negative effect on future
vaccine administrations has yet to be deter-
mined. We can hypothesize that it would
boost the immune response to a future vacci-
nation meant to protect animals or humans
from the LT holotoxin; however, if LT-B were
to be used as an adjuvant in a vaccine against a
heterologous antigen, the response to that vac-
cine may be altered. Additionally, further
research is needed to ensure that LT-B admin-
istered orally will not promote the develop-
ment of tolerance to vaccines or allergies to
co-administered food proteins. 
This study provides data that are the ﬁrst of
their kind to begin assessing the consequences
of accidental consumption of LT-B in maize.
Risk assessment for noncancerous, nontoxic
transgenic plants is evolving and includes the
use of uncertainty factors to extrapolate from
animals to humans (Kodell and Gaylor 1999).
A recent risk assessment by Wolt et al. (2006)
of human exposure to LT-B in transgenic
maize indicates that a dose 200-fold lower
than a functional dose in humans is small
enough to consider that maize unadulterated
from a toxicologic perspective. However, in
our mouse study, a dose 1,000-fold lower than
the functional 20-µg LT-B dose, 0.02 µg
LT-B was immunogenic and caused immune
priming in approximately half the mice. The
highest nonimmunostimulatory dose tested was
10,000-fold lower than the functional 20-µg
LT-B dose. Using this information, we can esti-
mate a safe, nonimmunogenic dose for
humans. Tacket et al. (2004) fed maize trans-
genic for LT-B to humans. The functional dose
in this study was 1.1 mg LT-B per 70-kg adult.
A dose 10,000-fold lower than this functional
dose is equivalent to 0.11 µg LT-B, which is
our best estimate for a nonimmunogenic dose
in humans.
Consuming low immunostimulatory doses
of LT-B does not result in adverse toxic effects,
as indicated by no changes in animal body
weight or overall health; however, the low dose
may be enough to alter immune responses. An
immune response to LT-B may not be harmful
on its own, but if accidental consumption were
to alter the way in which a person or animal
would later respond to an oral vaccine contain-
ing LT-B in transgenic maize, it could render
the vaccine less useful. For example, daily
exposure to LT-B may induce oral tolerance. If
accidental consumption of transgenic LT-B
maize were to occur daily (as opposed to the
intermittent feeding schedule used in this
study), this could lead to vaccine inefﬁciency as
well as a reduced ability of the immune system
to eliminate an ETEC infection. 
The data presented here apply to the inter-
mittent feeding schedule used. We understand
that mice exposed to the same doses of LT-B at
differing intervals may have different immune
responses. Further studies are needed to
compare intermittent and continuous feeding
regimens for transgenic maize. 
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